Cutler Group’s Regulus Therapeutics RGLS Stock Holding History

Cutler Group’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-113	Closed	-$4K	–	7174
2016 Q3	$4K	Buy	113 +23	+26%	+$9.46K	﹤0.01%	5177
2016 Q2	$2K	Buy	+90	New	+$64.5K	﹤0.01%	5726

Other funds holding RGLS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SDIC

South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cutler Group's RGLS Position: Q2 2017 in Review

Cutler Group sold out of Regulus Therapeutics (RGLS) in Q2 2017, closing a stake of 14 shares — an estimated $2K sold.

Cutler Group first reported a position in RGLS in Q4 2015 and held it in 6 quarters. The position peaked at $170K in Q1 2016. 46 funds tracked by Wall St. Rank hold RGLS as of Q2 2017.

Cutler Group reported no remaining Regulus Therapeutics position as of Q2 2017 after selling out during the quarter.
Cutler Group sold 14 Regulus Therapeutics shares in Q2 2017, an estimated $2K.
Cutler Group first reported a position in Regulus Therapeutics in Q4 2015 and held it in 6 quarters.
Cutler Group's Regulus Therapeutics position peaked at $170K in Q1 2016.
46 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2017.

Based on Cutler Group's 13F filing for Q2 2017, filed 11 Jul 2017.